Name: BLTE Income Statement - Belite Bio Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

BLTE - Belite Bio, Inc.

USD | NASDAQ | Healthcare

BLTE Income Statement - Belite Bio Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues
Revenues	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses
Research & Development	45.4	29.9	24.8	8.9	7.4	3.7
Selling General & Administrative	38.8	10.1	6.8	-	-	-
Operating Income
Operating Income	(84.2)	(40.0)	(31.7)	(12.8)	(9.8)	(5.7)
Non-Operating
Interest Income	6.6	3.7	0.1	0.0	0.0	0.0
Interest Expense	0.0	0.0	0.0	0.0	-	0.0
Income From Equity Investments
Tax & Net
Income Tax Expense	0.0	0.0	0.0	-	-	0.0
Net Income From Continuing Ops	(77.6)	(36.1)	(31.6)	(12.6)	(9.7)	(5.8)
Net Income From Discontinued Ops
Per Share
EPS Basic	(2.31)	(1.18)	(1.19)	(0.63)	(1.01)	(0.65)
EPS Diluted	(2.31)	(1.18)	(1.19)	(0.63)	(1.01)	(0.65)
Shares Basic
Supplementary Data
EBITDA	(84.0)	(39.8)	(31.5)	(12.8)	(9.8)	(5.7)
EBIT	(84.2)	(40.0)	(31.7)	(12.8)	(9.8)	(5.7)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)